Bp Plc Invests $3.58 Million in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

BP PLC purchased a new stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 23,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,577,000.

Several other institutional investors have also recently made changes to their positions in the stock. Shaker Investments LLC OH bought a new stake in Jazz Pharmaceuticals PLC during the second quarter valued at approximately $883,000. Korea Investment CORP boosted its stake in Jazz Pharmaceuticals PLC by 436.6% in the second quarter. Korea Investment CORP now owns 22,000 shares of the specialty pharmaceutical company’s stock valued at $3,421,000 after buying an additional 17,900 shares in the last quarter. Brave Asset Management Inc. bought a new stake in Jazz Pharmaceuticals PLC during the second quarter valued at approximately $258,000. World Asset Management Inc boosted its stake in Jazz Pharmaceuticals PLC by 1.9% in the second quarter. World Asset Management Inc now owns 1,441 shares of the specialty pharmaceutical company’s stock valued at $224,000 after buying an additional 27 shares in the last quarter. Finally, Emerald Advisers Inc. PA bought a new stake in Jazz Pharmaceuticals PLC during the second quarter valued at approximately $1,281,000. 87.22% of the stock is owned by institutional investors.

Shares of Jazz Pharmaceuticals PLC (JAZZ) opened at 144.40 on Friday. Jazz Pharmaceuticals PLC has a one year low of $95.80 and a one year high of $163.75. The company has a market cap of $8.67 billion, a P/E ratio of 22.24 and a beta of 1.10. The stock’s 50 day moving average is $153.33 and its 200-day moving average is $147.61.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.85 by $0.13. The firm had revenue of $394.39 million for the quarter, compared to analysts’ expectations of $410.83 million. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The firm’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.67 earnings per share. Equities research analysts forecast that Jazz Pharmaceuticals PLC will post $10.87 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Bp Plc Invests $3.58 Million in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)” was first posted by BNB Daily and is the property of of BNB Daily. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.baseball-news-blog.com/2017/08/19/bp-plc-purchases-new-stake-in-jazz-pharmaceuticals-plc-nasdaqjazz-updated.html.

JAZZ has been the topic of several analyst reports. Wells Fargo & Company reissued an “outperform” rating and set a $177.00 price target (down from $178.00) on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, August 10th. BidaskClub cut shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research report on Thursday, August 3rd. Zacks Investment Research cut shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, May 2nd. Piper Jaffray Companies reissued an “overweight” rating and set a $182.00 price target on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, June 7th. Finally, Vetr raised shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $151.11 price target on the stock in a research report on Tuesday, June 6th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nineteen have issued a buy rating to the company’s stock. Jazz Pharmaceuticals PLC presently has an average rating of “Buy” and an average price target of $182.72.

In other news, SVP Paul Treacy sold 1,304 shares of Jazz Pharmaceuticals PLC stock in a transaction on Monday, August 14th. The stock was sold at an average price of $143.32, for a total transaction of $186,889.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Paul L. Berns sold 662 shares of Jazz Pharmaceuticals PLC stock in a transaction on Friday, August 11th. The stock was sold at an average price of $142.37, for a total value of $94,248.94. Following the sale, the director now owns 6,599 shares of the company’s stock, valued at $939,499.63. The disclosure for this sale can be found here. Insiders have sold 12,566 shares of company stock valued at $1,921,138 over the last ninety days. 4.30% of the stock is owned by insiders.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply